Healthy Clinical Trial
Official title:
Multimodal Brain Decoding of Pain Sensitivity
Verified date | September 2022 |
Source | National Yang Ming University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Pain is the leading cause of disability worldwide. However, the pain sensitivity of individuals varies to a large extent, which often results in the mismatch between clinical diagnosis or treatment and individual's actual needs. There are still no established objective indicators for comparisons between individuals. This integrated pilot project is the first large-scale, multi-modal brain decoding study for pain sensitivity. We will explore the brain network signature of pain sensitivity by analyzing electroencephalogram (EEG) signals and magnetic resonance imaging (MRI.) Meanwhile, we will integrate the innate, environmental, and humanity factors with aforementioned brain network signatures to establish multi- modal objective model of pain sensitivity using machine learning. This research team is composed of more than 30 physicians, scientists, and IT experts, along with international collaborators with expertise in the fields of neuroscience, medical imaging, and human philosophy. The five elite groups constitute this international research team and establish five multi-disciplinary sub-projects: Sub-project A: Pain sensitivity and associated innate and environmental factors Sub-project B: Electrophysiological brain signatures of pain sensitivity Sub-project C: MRI brain signatures of pain sensitivity Sub-project D: Innovative brain computer interface (BCI) technology in pain sensitivity measurement and prediction Sub-project E: Pain and Art: neuro-mental mechanisms and potential applications There are three key features of this integrated project: scientific novelty, technology and humanity. In terms of scientific novelty, in addition to machine learning and big data applications, we will focus on the deep brain structure such as brainstem, in which the image acquisition has been difficult in the past. We will develop an MRI sequence and EEG protocol optimized for brainstem. In terms of technology, we will develop a wearable EEG cap implanted with algorithm chip for clinical measurement to decode the pain sensitivity real time. In terms of humanity, we will combine music and painting appreciation to explore their impact on brain signatures related to pain sensitivity. Furthermore, we will develop potential applications of art intervention in pain modulation. We expect this pilot project to achieve the four following goals: 1. To establish a Taiwan database of pain sensitivity. Meanwhile, to clarify the interactions between the innate and environmental factors of the individual and the brain network, and to identify brain signatures related to pain sensitivity. (sub- projects A, B, C) 2. To confirm the brain signatures for predicting the pain sensitivity using machine learning. In addition, to develop wearable devices such as EEG cap for large sample screening by combining the brain-computer interface through the industry-university cooperation (sub-projects B, C, D) 3. To explore the plasticity of brain signatures related to pain sensitivity by sensory modulation such as music, painting appreciation or transcutaneous electrical nerve stimulation, and to explore the application potential for pain modulation (sub-projects B, C, D, E) 4. Based on the cooperation model of this international research team, we will cultivate young researchers, and promote academic interactions among different team members, and improve the international visibility and competitiveness of Taiwan (sub-projects A, B, C, D, E)
Status | Active, not recruiting |
Enrollment | 100 |
Est. completion date | December 2022 |
Est. primary completion date | November 20, 2020 |
Accepts healthy volunteers | |
Gender | All |
Age group | 20 Years to 55 Years |
Eligibility | Inclusion Criteria: - aged 20-55 - understand the study and provide informed consent Exclusion Criteria: - Any acute or chronic condition that could potentially affect pain perception, including diabetes, hypertension, peripheral and central nervous disorders - Presence of any pain disorder or suffering from any acute pain within 2 weeks - History of any neurological disease, except primary headache with headache frequency less than 1 days per month - Psychiatric disorders including major depressive disorder, post-traumatic stress disorder, personality disorder, bipolar disorder, and schizophrenia - History of substance abuse, including alcohol, analgesic, and illicit drugs. - Any condition that would make participants contra-indicated to magnetic resonance imaging (MRI) scans transcutaneous electrical nerve stimulation (TENS), or electroencephalography (EEG). |
Country | Name | City | State |
---|---|---|---|
Taiwan | National Yang-Ming University | Taipei city |
Lead Sponsor | Collaborator |
---|---|
National Yang Ming University |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | sensory thresholds | Using quantitative sensory testing (QST) to evaluate the sensory threshold | 30 minutes | |
Primary | EEG change (1) | Linear analysis of EEG with pain sensitivity | 10 minutes | |
Primary | EEG change (2) | Nonlinear analysis of EEG with pain sensitivity | 10 minutes | |
Primary | MRI | Analysis of MRI correlatin with pain sensitivity | 90 minutes | |
Primary | fMRI | Analysis of fMRI correlatin with pain sensitivity | 90 minutes | |
Primary | Humoral relationship (1) | Test the related hormones to evaluate the relationship with sensitivity | 5 minutes | |
Primary | Humoral relationship (2) | Test the related cytokines to evaluate the relationship with sensitivity | 5 minutes | |
Secondary | innate and environmental factors associated with pain sensitivity | explory potential factors that may influence the pain sensitivity | 5 minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |